606
M. E. Di Francesco et al.
2. Liang, T.J.; Heller, T. Pathogenesis of hepatitis C—associated hepatocellular carcinoma. Gastroen-
terology 2004, 127(5 Suppl 1), S62–S71.
3. Feld, J.J.; Hoofnagle, J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis
C. Nature 2005, 436, 967–972.
4. Manns, M.P.; Wedemeyer, H.; Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and
complications. Gut 2006, 55(9), 1350–1359.
5. Vermehren, J.; Sarrazin, C. Preparation of HCV NS3 and NS5B proteins to support small-molecule
drug discovery. Clin. Mirobiol. Infect. 2011, 17(2), 122–134.
6. Lin, C.; Kwong, A.D.; Perni, R.B. Discovery and development of VX-950, a novel, covalent, and
reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug targets 2006, 6(1),
3–16.
7. Venkatraman, S.; Bogen, S.L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y.T.; Lovey, R.;
Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam,
B. Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase,
R.; Hart, A.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo,
Z.; Prongay, A.; Madison, V.; Broske, L.; Cui, X. Cheng, K.-C.; Hsieh, Y.; Brisson, J.-M.; Prelusky,
D.; Korfmacher, W.; White, R. Bogdanowich-Knipp, S.; Pavlovsky, A.; Bradley, P.; Saksena, A. K.;
Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of (1R,5S)-N-[3-amino-1-
(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-
dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034),
a
selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic
agent for the treatment of hepatitis C infection. J. Med. Chem. 2006, 49(20), 6074–6086.
8. Kolykhalov, A.A.; Mihalik, K.; Feinstone, S.M.; Rice, C.M. Hepatitis C virus-encoded enzymatic activ-
ities and conserved RNA elements in the 3ꢁ nontranslated region are essential for virus replication
in vivo. J. Virol. 2000, 74, 2046–2051.
9. Koch, U.; Narjes, F. Recent progress in the development of inhibitors of the hepatitis C RNA-
dependent-RNA-polymerase. Curr. Top. Med. Chem. 2007, 7(13), 1302–1329.
10. Carroll, S.S.; Olsen, D.B. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. Disord.
Drug Targets 2006, 6(1), 17–29.
11. Birerdinc, A.; Younossi, Z.M. Emerging therapies for hepatitis C virus. Expert Opin. Emerg. Drugs 2010,
15(4), 535–544.
12. (a) Sommadossi, J.P.; La Colla, P.; Storer, R.; Gosselin, G. 2ꢁ- and 3ꢁ-nucleoside prodrugs for treating
Flaviviridae infections PCT Int. Appl. WO 2004/003000, 2004; (b) Pierra, C.; Benzaria, S.; Amador,
A.; Moussa, A.; Mathieu, S.; Storer, C.; Gosselin, G. NM 283, an efficient prodrug of the potent
anti-HCV agent 2ꢁ-C-methylcytidine Nucleos. Nucleot. Nucl. 2005, 24(5-7), 767–770 c) Toniutto, P.;
Fabris, C.; Bitetto, D.; Fornasiere, E.; Rapetti, R.; Pirisi, M. Valopicitabine dihydrochloride: a specific
polymerase inhibitor of hepatitis C virus. Curr. Opin. Investig. Drugs 2007, 8(2), 150–158.
13. Jiang, W.R.; Ali, S.; LePogam, S.; Danoel, C.; Chiu, S.; Kretz, T.; Najera, P.A.; Furman, N.; Cammack,
N.; Symons, J. Inhibition of HCV replication by PSI-6130: characterization of activity in the HCV
replicon system. J. Hepatol. 2007, 46(S1), S228.
14. Sofia, M.J.; Bao, D.; Chang, W.; Du, J.; Nagarathnam, D.; Rachakonda, S.; Reddy, P.G.; Ross, B.S.;
Wang, P.; Zhang, H.R.; Bansal, S.; Espiritu, C.; Keilman, M.; Lam, A.M.; Steuer, H.M.; Niu, C.; Otto,
M.J.; Furman, P.A. Discovery of a β-d-2ꢁ-deoxy-2ꢁ-α-fluoro-2ꢁ-β-C-methyluridine nucleotide prodrug
(PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 2010, 53(19), 7202–7218.
15. (a) Olsen, D.B.; Eldrup, A.B.; Bartholomew, L.; Bhat, B.; Bosserman, M.R.; Ceccacci, A.; Colwell, L.F.;
Fay, J.F.; Flores, O.A.; Getty, K.L.; Grobler, J.A.; LaFemina, R.L.; Markel, E.J.; Migliaccio, G.; Prhave,
M.; Stahlut, M.W.; Tomassini, J.E.; MacCoss, M.; Hazuda, D.J.; Carroll, S.S. A 7-deaza-adenosine
analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharma-
cokinetic properties. Antimicrob. Agents Chemother. 2004, 48(10), 3944–3953; (b) Carroll, S.S.; Davies,
M.E.; Handt, L.; Koeplinger, K.; Zhang, R.; Ludmerer, S.W.; MacCoss, M.; Hazuda, D.J.; Olsen, D.B.
Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected
chimpanzees. Hepatology 2006, 44(S1), 535A.
16. Carroll, S.S.; Tomassini, J.E.; Bosserman, M.; Getty, K.; Stahlhut, M.W.; Eldrup, A.B.; Bhat, B.; Hall,
D.; Simcoe, A.L.; LaFemina, R.; Rutkowski, C.A.; Wolanski, B.; Yang, Z.; Migliaccio, G.; De Francesco,
R.; Kuo, L.C.; MacCoss, M.; Olsen, D.B. Inhibition of hepatitis C virus RNA replication by 2ꢁ-modified
nucleoside analogs. J. Biol. Chem. 2003, 278(14), 11979–11984.